Pushkal Garg, EVP Chief R&D at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 11,786 shares at $449.99 ($5.3M) on 2025-10-03, disclosed to the SEC on 2025-10-03.
Scheduled sale ($5.3M) by EVP Chief R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $446.53 | 115 | $51K | 1.0% |
| 2 | $446.53 | 115 | $51K | 1.0% |
| 3 | $447.92 | 56 | $25K | 0.5% |
| 4 | $448.77 | 180 | $81K | 1.5% |
| 5 | $448.77 | 180 | $81K | 1.5% |
| 6 | $449.79 | 249 |
| $112K |
| 2.1% |
| 7 | $449.79 | 249 | $112K | 2.1% |
| 8 | $450.81 | 541 | $244K | 4.6% |
| 9 | $450.81 | 541 | $244K | 4.6% |
| 10 | $451.86 | 332 | $150K | 2.8% |
| 11 | $451.86 | 332 | $150K | 2.8% |
| 12 | $452.69 | 668 | $302K | 5.7% |
| 13 | $452.69 | 668 | $302K | 5.7% |
| 14 | $453.77 | 329 | $149K | 2.8% |
| 15 | $453.77 | 329 | $149K | 2.8% |
| 16 | $454.84 | 244 | $111K | 2.1% |
| 17 | $454.84 | 244 | $111K | 2.1% |
| 18 | $455.82 | 73 | $33K | 0.6% |
| 19 | $457.43 | 147 | $67K | 1.3% |
| 20 | $457.43 | 147 | $67K | 1.3% |
| 21 | $457.64 | 3 | $1K | 0.0% |
| 22 | $449.99 | 682 | $307K | 5.8% |
| 23 | $449.99 | 682 | $307K | 5.8% |
| 24 | $450.63 | 810 | $365K | 6.9% |
| 25 | $450.63 | 810 | $365K | 6.9% |
| 26 | $451.76 | 898 | $406K | 7.6% |
| 27 | $451.76 | 898 | $406K | 7.6% |
| 28 | $453.51 | 417 | $189K | 3.6% |
| 29 | $453.51 | 417 | $189K | 3.6% |
| 30 | $454.37 | 215 | $98K | 1.8% |
| 31 | $454.37 | 215 | $98K | 1.8% |
| Total | $451.76 avg | 11,786 | $5.3M | 100% |
| Filing → |
| ALNY | SELL | 2026-03-02 | $1.5M | — | Filing → |
| ALNY | SELL | 2026-02-17 | $695K | — | Filing → |
| ALNY | SELL | 2026-01-14 | $548K | — | Filing → |